Cushing Syndrome: How Cortisol Excess Rewrites the Body

What Cushing Syndrome Is and Why It Matters

Cushing syndrome is the constellation of signs, symptoms, and metabolic derangements caused by prolonged exposure to excess glucocorticoid. It is defined by the effect (hypercortisolism) rather than a single cause. The distinction that matters clinically is:

• Cushing syndrome — any cause of glucocorticoid excess.
• Cushing disease — the specific subset caused by an ACTH-secreting pituitary adenoma (Harvey Cushing's original 1932 description). It accounts for roughly 70–80% of endogenous cases.

The single most common cause overall, however, is iatrogenic: chronic prednisone, dexamethasone, or inhaled/intra-articular steroids. It matters because cortisol is a master regulator — it touches glucose metabolism, immune function, vascular tone, bone turnover, and mood. Sustained excess therefore produces a multi-system disease with a mortality up to 4–5× normal when untreated, dominated by cardiovascular events, venous thromboembolism, and opportunistic infection. Early recognition is disproportionately valuable because the biochemical and structural damage is largely reversible once the source is removed.

The Mechanism: How Cortisol Rewrites the Cell

Cortisol is lipophilic, so it crosses the plasma membrane and binds the intracellular glucocorticoid receptor (GR / NR3C1). The ligand-bound receptor sheds chaperones (HSP90), translocates to the nucleus, and acts as a transcription factor at glucocorticoid response elements, up- or down-regulating hundreds of genes.

• Gluconeogenesis ↑: GR induces PEPCK and glucose-6-phosphatase in liver while inducing peripheral insulin resistance → hyperglycemia, steroid diabetes.
• Protein catabolism: muscle and skin protein is broken down for gluconeogenic substrate → proximal myopathy, thin skin, striae.
• Lipolysis + redistribution: fat is mobilized peripherally but deposited centrally (face, dorsocervical, supraclavicular) — the classic truncal pattern.
• Immunosuppression: transrepression of NF-κB and AP-1 suppresses cytokines and lymphocytes.
• Mineralocorticoid spillover: at very high concentrations cortisol overwhelms renal 11β-HSD2 (which normally inactivates it to cortisone), activating the mineralocorticoid receptor → sodium retention, hypokalemia, hypertension.

In ACTH-dependent disease, the pituitary or ectopic tumor loses normal negative feedback, so cortisol no longer shuts off ACTH — the loop runs open.

Clinical Presentation and Classic Signs

The phenotype reflects the mechanism directly. The most discriminating features (those that best separate true Cushing from simple obesity) are proximal muscle weakness, wide purple striae (>1 cm), easy bruising, and facial plethora.

• Fat redistribution: moon facies, dorsocervical fat pad ("buffalo hump"), supraclavicular fullness, central obesity with thin limbs.
• Skin: thin, atrophic skin; wide violaceous abdominal striae; ecchymoses; poor wound healing; hyperpigmentation when ACTH (and its POMC-derived MSH) is very high (ectopic/Cushing disease).
• Musculoskeletal: proximal myopathy (difficulty rising from a chair), osteoporosis, fragility fractures.
• Metabolic/vascular: hypertension, glucose intolerance/diabetes, dyslipidemia, hypokalemic metabolic alkalosis.
• Reproductive/androgenic: menstrual irregularity, hirsutism, acne (adrenal androgen excess).
• Neuropsychiatric: depression, anxiety, insomnia, cognitive impairment.

A rapidly progressive course with severe hypokalemia, hyperpigmentation, and weight loss (rather than gain) suggests ectopic ACTH from an aggressive tumor.

Diagnosis: Confirm, Then Localize

Diagnosis is a two-step logic: (1) prove hypercortisolism, then (2) find the source. First exclude exogenous steroids by history.

Step 1 — screen (need ≥2 abnormal):

• 1 mg overnight dexamethasone suppression test: give 1 mg at 11 pm; a morning cortisol >1.8 µg/dL (50 nmol/L) is a failure to suppress → positive.
• Late-night salivary cortisol: loss of the normal nocturnal nadir (elevated 11 pm–midnight value).
• 24-hour urinary free cortisol: elevated (typically >3–4× upper normal is highly specific).

Step 2 — localize with plasma ACTH:

• ACTH suppressed (<5–10 pg/mL): ACTH-independent → adrenal cause → adrenal CT/MRI.
• ACTH normal/high: ACTH-dependent → pituitary MRI. Because ~10% of adults have incidental pituitary lesions, use the high-dose (8 mg) dexamethasone suppression and/or CRH stimulation; the gold standard to separate pituitary from ectopic is inferior petrosal sinus sampling (central-to-peripheral ACTH gradient ≥2 at baseline, ≥3 after CRH).

Management at a Mechanism Level

Treatment targets the source and, when needed, blocks cortisol pharmacologically.

• Surgery (definitive): Transsphenoidal resection of the pituitary adenoma for Cushing disease (remission ~70–90% for microadenomas); adrenalectomy for adrenal tumors; resection of the ectopic source when localizable.
• Steroidogenesis inhibitors (block cortisol synthesis): ketoconazole and metyrapone (inhibits 11β-hydroxylase/CYP11B1), and osilodrostat (potent 11β-hydroxylase inhibitor). Etomidate IV is used for acute, severe hypercortisolism.
• Pituitary-directed: pasireotide (somatostatin analog, SSTR5) and cabergoline (dopamine agonist) reduce ACTH output in Cushing disease.
• Glucocorticoid-receptor blockade: mifepristone antagonizes the GR — useful for the hyperglycemia of Cushing when surgery fails (does not lower cortisol; monitor clinically).
• Bilateral adrenalectomy: a definitive last resort — watch for Nelson syndrome (aggressive corticotroph tumor growth with marked hyperpigmentation).

Because chronic excess suppresses the axis, curing the source causes transient adrenal insufficiency — patients need glucocorticoid replacement and a taper until the HPA axis recovers.

Mimics, Pitfalls, and Significance

The biggest trap is pseudo-Cushing states — conditions with real, mild hypercortisolism that mimic the picture: obesity, poorly controlled diabetes, chronic alcohol use, depression, and physiologic stress. These can cause false-positive screening tests. Distinguishing tools include the dexamethasone-CRH test and repeat late-night salivary cortisol; true Cushing shows loss of circadian rhythm and non-suppression.

• Don't diagnose during acute illness — stress transiently raises cortisol; defer testing.
• Estrogen (oral contraceptives, pregnancy) raises cortisol-binding globulin and total serum cortisol → false positives; stop estrogen ~6 weeks before testing.
• Cyclic Cushing can produce intermittently normal tests — repeat over time.
• Rapid onset + severe hypokalemia + weight loss → think ectopic ACTH, not classic pituitary disease.

The significance is that Cushing is a reversible cause of hypertension, diabetes, osteoporosis, and psychiatric disease. Recognizing the discriminating signs early — before irreversible vascular and skeletal damage — is where clinical judgment saves the most.

Localizing endogenous Cushing syndrome by ACTH and dynamic testing

Feature	Cushing disease (pituitary)	Ectopic ACTH	Adrenal (ACTH-independent)
Share of endogenous cases	~70–80%	~5–10%	~15–20%
Plasma ACTH	Normal to high	High to very high	Low / suppressed (<5–10 pg/mL)
High-dose (8 mg) dexamethasone	Suppresses cortisol >50%	No suppression	No suppression
CRH stimulation	ACTH/cortisol rise	No response (usually)	No response
Typical lesion	Small (<6 mm) pituitary microadenoma	Small-cell lung ca, carcinoid, medullary thyroid	Adrenal adenoma or carcinoma
Confirmatory localization	Inferior petrosal sinus sampling	CT chest/abdomen, Ga-68 DOTATATE PET	Adrenal CT/MRI